Rosen Law Firm reminds purchasers of Zoetis securities between January 14, 2025 and May 6, 2026 of the July 27, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that throughout the class period, Zoetis made false or misleading statements about its Companion Animal products and failed to disclose weakening veterinarian adoption of Librela following FDA safety warnings, significant market share losses for Simparica Trio to a lower-priced competitor, and substantial market share erosion for Apoquel and Cytopoint to a newly launched competing treatment. Investors who purchased Zoetis securities during the class period may be entitled to compensation through a contingency fee arrangement. To join the class action or seek lead plaintiff appointment, investors must contact Rosen Law Firm before the deadline.
Zoetis IncSecurities class action lawsuit alleges false statements and undisclosed risks, creating legal liability and reputational damage.